News NICE rejects Eisai's Halaven in new breast cancer use NICE rejects drug after finding gap in clinical data
Views & Analysis Medical affairs: leading a transformation in medicines Medical Affairs is leading the change towards a more patient and customer-centric, data driven industry.
Views & Analysis Bureaucracy and duplication: the reality of the PPRS Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
News NICE backs funding for Pfizer, Novartis breast cancer drugs Pfizer had been giving drug free to NHS before decision
Views & Analysis Mind the (implementation) gap Examining the true impact of a positive health technology assessment (HTA).
News Reimbursement remains biggest barrier to precision drugs Reimbursement more of a barrier than regulation
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
